- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05896683
A Study of Lazertinib (JNJ-73841937) Tablet in Healthy Adult Participants
September 13, 2023 updated by: Janssen Research & Development, LLC
A Phase 1, Open-label, Randomized, 2-Part, 2-Way Crossover Study in Healthy Adult Participants to Assess the Relative Bioavailability of Tablet Formulations of Lazertinib (JNJ-73841937)
The purpose of this study is to assess the extent of availability of drug to the body of four different lazertinib tablet formulations at a single oral dose under fasted conditions in healthy adult participants.
Study Overview
Study Type
Interventional
Enrollment (Actual)
72
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Study Contact
- Phone Number: 844-434-4210
- Email: Participate-In-This-Study@its.jnj.com
Study Locations
-
-
-
Edegem, Belgium, 2650
- SGS Belgium NV
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Healthy on the basis of physical examination, medical history (at screening only), vital signs, and 12-lead electrocardiogram (ECG) performed at screening and at admission to the study site in Intervention Period 1
- Body weight not less than 50.0 kilograms (kgs) and body mass index (BMI, weight/height^2) within the range 19.0-30.0 kg/m^2 (inclusive) at screening
- All female participants must have a negative highly sensitive serum beta-human chorionic gonadotropin (beta-HCG) test at screening and a negative urine pregnancy test on Day -1 of Intervention Period 1
- A male participant must agree not to donate sperm for the purpose of reproduction during the study and for a minimum of 6 months after receiving the last dose of study intervention
- Must sign an ICF indicating that the participant understands the purpose of, and procedures required for, the study and is willing to participate in the study
Exclusion Criteria:
- History of or current clinically significant medical illness including (but not limited to) cardiac arrhythmias or other cardiac disease, hematologic disease, coagulation disorders (including any abnormal bleeding or blood dyscrasias), lipid abnormalities, significant pulmonary disease, including bronchospastic respiratory disease and interstitial lung disease, diabetes mellitus (with the exception of history of gestational diabetes), hepatic insufficiency, inflammation bowel disease/Crohn's disease, thyroid disease, neurologic or psychiatric disease, infection, or any other illness that the investigator considers should exclude the participant or that could interfere with the interpretation of the study results
- History of stomach or intestinal surgery or resection, including cholecystectomy, that would potentially alter absorption or excretion of orally administered drugs
- History of malignancy within 5 years before screening
- Use of any prescription or nonprescription medication (including vitamins and herbal supplements), except for paracetamol, ibuprofen, and stable hormone replacement therapy (in postmenopausal female participants only) within 14 days before the first dose of study intervention is scheduled until completion of the study
- History of human immunodeficiency virus (HIV) antibody positive, or tests positive for HIV at screening
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part 1: Sequence AB
Participants will receive intervention A (lazertinib reference formulation) on Day 1 of intervention period 1.
After washout period of 14 to 21 days, participants will receive intervention B (lazertinib test formulation) on Day 1 of intervention period 2.
|
Lazertinib will be administered orally.
Other Names:
|
Experimental: Part 1: Sequence BA
Participants will receive intervention B (lazertinib test formulation) on Day 1 of intervention period 1.
After washout period of 14 to 21 days, participants will receive intervention A (lazertinib reference formulation) on Day 1 of intervention period 2.
|
Lazertinib will be administered orally.
Other Names:
|
Experimental: Part 2: Sequence CD
Participants will receive Intervention C (lazertinib reference formulation) on Day 1 of intervention period 1.
After washout period of 14 to 21 days, participants will receive intervention D (lazertinib test formulation) on Day 1 of intervention period 2.
|
Lazertinib will be administered orally.
Other Names:
|
Experimental: Part 2: Sequence DC
Participants will receive intervention D (lazertinib test formulation) on Day 1 of intervention period 1.
After washout period of 14 to 21 days, participants will receive intervention C (lazertinib reference formulation) on Day 1 of intervention period 2.
|
Lazertinib will be administered orally.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1: Maximum Observed Plasma Concentration (Cmax) of Lazertinib
Time Frame: Pre dose up to 168 hours post dose on Day 1
|
Cmax is defined as maximum observed plasma concentration of lazertinib.
|
Pre dose up to 168 hours post dose on Day 1
|
Part 2: Maximum Observed Plasma Concentration (Cmax) of Lazertinib
Time Frame: Pre dose up to 168 hours post dose on Day 1
|
Cmax is defined as maximum observed plasma concentration of lazertinib.
|
Pre dose up to 168 hours post dose on Day 1
|
Part 1: Area Under the Plasma Concentration-time Curve from Time 0 to 72 Hours (h) (AUC[0-72h]) of Lazertinib
Time Frame: Pre dose up to 72 hours post dose on Day 1
|
AUC(0-72h) is the area under the plasma concentration-time curve from time 0 to 72 hours.
|
Pre dose up to 72 hours post dose on Day 1
|
Part 2: Area Under the Plasma Concentration-time Curve from Time 0 to 72h (AUC[0-72h]) of Lazertinib
Time Frame: Pre dose up to 72 hours post dose on Day 1
|
AUC(0-72h) is the area under the plasma concentration-time curve from time 0 to 72 hours.
|
Pre dose up to 72 hours post dose on Day 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Adverse Events (AEs)
Time Frame: Up to 8 Weeks
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product.
An AE does not necessarily have a causal relationship with the intervention.
|
Up to 8 Weeks
|
Number of Participants With Serious Adverse Events (SAEs)
Time Frame: Up to 8 Weeks
|
A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
|
Up to 8 Weeks
|
Number of Participants With AEs by Severity
Time Frame: Up to 8 Weeks
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product.
Number of participants with AEs by severity will be reported.
Severity will be graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0.
Severity scale ranges from grade 1 to 5, where Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening and Grade 5= death related to adverse event.
|
Up to 8 Weeks
|
Number of Participants With Change From Baseline in Clinical Laboratory Test Values
Time Frame: Up to 8 Weeks
|
Number of participants with change from baseline in clinical laboratory test values (including hematology and serum chemistry) will be reported.
|
Up to 8 Weeks
|
Number of Participants With Change From Baseline in 12-lead Electrocardiograms (ECGs)
Time Frame: Up to 8 Weeks
|
Number of participants with change from baseline in 12-lead ECGs will be reported.
|
Up to 8 Weeks
|
Number of Participants With Change From Baseline in Vital Signs
Time Frame: Up to 8 Weeks
|
Number of participants with change from baselines in vital signs (including temperature [oral], pulse rate, and blood pressure) will be reported.
|
Up to 8 Weeks
|
Number of Participants With Change From Baseline in Physical Examination
Time Frame: Up to 8 Weeks
|
Number of participants with change from baseline in physical examination (including height and body weight) will be reported.
|
Up to 8 Weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 30, 2023
Primary Completion (Actual)
September 1, 2023
Study Completion (Actual)
September 1, 2023
Study Registration Dates
First Submitted
June 1, 2023
First Submitted That Met QC Criteria
June 1, 2023
First Posted (Actual)
June 9, 2023
Study Record Updates
Last Update Posted (Actual)
September 14, 2023
Last Update Submitted That Met QC Criteria
September 13, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR109314
- 73841937NSC1010 (Other Identifier: Janssen Research & Development, LLC)
- 2022-502814-99-00 (Registry Identifier: EUCT number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency.
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Lazertinib
-
Yuhan CorporationCompletedHealthy Adult VolunteersKorea, Republic of
-
Yonsei UniversityNot yet recruitingNon Small Cell Lung CancerKorea, Republic of
-
Myung-Ju AhnRecruitingNSCLCKorea, Republic of
-
Konkuk University Medical CenterYuhan CorporationRecruitingNon Small Cell Lung CancerKorea, Republic of
-
Janssen Research & Development, LLCCompleted
-
Yuhan CorporationApproved for marketing
-
Jin Hyoung KangRecruitingLung NeoplasmsKorea, Republic of
-
Yonsei UniversityNot yet recruitingNon Small Cell Lung CancerKorea, Republic of
-
Yonsei UniversityNot yet recruitingNon-small Cell Lung CancerKorea, Republic of
-
Samsung Medical CenterNot yet recruiting